Lorlatinib in ALK- or ROS1-positive non-small cell lung cancer patients: Experience from an early access program in Turkey

Basit Öğe Kaydı
dc.contributor.authorKılıçkap, Saadettin
dc.contributor.authorDemirci, Umut
dc.contributor.authorBuğdaycı, Fatma
dc.contributor.authorTural, Deniz
dc.contributor.authorKorkmaz, Taner
dc.contributor.authorPaydaş, Semra
dc.contributor.authorYılmaz, Coşkun
dc.contributor.authorTuna, Hande
dc.contributor.authorSezer, Ahmet
dc.contributor.authorYeşil Çinkir, Havva
dc.contributor.authorErman, Münire
dc.contributor.authorEralp, Yeşim
dc.contributor.authorÇabuk, Devrim
dc.contributor.authorIşıkdoğan, Abdurrahman
dc.contributor.authorDemirkazık, Ahmet
dc.contributor.authorKaraoğlu, Aziz
dc.contributor.authorYazılıtaş, Doğan
dc.contributor.authorÇay Şenler, Filiz
dc.contributor.authorYumuk, Perran Fulden
dc.contributor.authorCoşkun, Hatice
dc.contributor.authorYıldız, İbrahim
dc.contributor.authorÖztop, İlhan
dc.contributor.authorBeypınar, İsmail
dc.contributor.authorAydın, Kübra
dc.contributor.authorKaplan, M.
dc.contributor.authorMeydan, Nezih
dc.contributor.authorÖlmez, Ömer Fatih
dc.contributor.authorSeber, Samile
dc.contributor.authorArslan, Çağatay
dc.contributor.authorŞendur, Mehmet Ali Nahit
dc.contributor.authorÇiçin, İrfan
dc.date.accessioned2019-12-25T07:56:49Z
dc.date.available2019-12-25T07:56:49Z
dc.date.issued2019
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractBackground: Lorlatinib, a third generation ALK and ROS1 inhibitor, is indicated for the treatment of patients with ALK+ metastatic NSCLC whose disease has progressed on crizotinib and at least one second-generation ALK inhibitor. The aim of this study is to evaluate the efficacy and safety of lorlatinib in an Expanded Access Program (EAP) in Turkey. Method: The EAP was open-label, multicenter, and single-arm. Patients were eligible to receive lorlatinib (100 mg po/day) if they had advanced stage ALK-or ROS1-positive NSCLC and had progressed on crizotinib and/or second generation ALK inhibitors such as ceritinib or alectinib. The primary endpoint was PFS with lorlatinib. Secondary endpoints were objective response rate, overall survival, and safety.
dc.identifier.citationKılıçkap, S., Demirci, U., Buğdaycı, F., Tural, D., Korkmaz, T., Paydaş, S. ... Çiçin, İ. (2019). Lorlatinib in ALK- or ROS1-positive non-small cell lung cancer patients: Experience from an early access program in Turkey. Journal of Thoracic Oncology içinde (S558-S559. ss.). Elsevier Science. https://doi.org/10.1016/j.jtho.2019.08.1166
dc.identifier.doi10.1016/j.jtho.2019.08.1166
dc.identifier.endpageS559
dc.identifier.issn1556-0864
dc.identifier.issn1556-1380
dc.identifier.issue10
dc.identifier.startpageS558
dc.identifier.urihttps://doi.org/10.1016/j.jtho.2019.08.1166
dc.identifier.urihttps://hdl.handle.net/20.500.12511/4670
dc.identifier.volume14
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherElsevier Science
dc.relation.ispartofJournal of Thoracic Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectALK Positive
dc.subjectROS1 Positive
dc.subjectLorlatinib
dc.subjectAdvanced Stage Lung Cancer
dc.titleLorlatinib in ALK- or ROS1-positive non-small cell lung cancer patients: Experience from an early access program in Turkey
dc.typeConference Object

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Olmez-Omer-2019.pdf
Boyut:
419.92 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Bildiri Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu